Theodosia Teo - Concepedia

Author

Theodosia Teo

University of South Australia ORCID

Also Known As

Teo, Theodosia, Theodosia Teo

Publications

842

Citations

H-Index

Concepts

All Affiliations

University of South Australia Centre for Cancer Biology University of Nottingham Cardiff University The University of Adelaide

About

Theodosia Teo is an author at University of South Australia specializing in medicine, medicinal chemistry, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	268
2	Natural Sciences	5	5	126
3	Biochemistry	5	5	126
4	Cell Biology	3	3	78
5	Biomolecular Engineering	1	1	68

Theodosia Teo

Publications

543

Citations

H-Index

Page 1

	Year	Citations
Discovery of 5‐(2‐(Phenylamino)pyrimidin‐4‐yl)thiazol‐2(3<i>H</i>)‐one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation Sarah Diab, Theodosia Teo, Malika Kumarasiri, ChemMedChem	2014	80
Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-<i>N</i>-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation Solomon Tadesse, Mingfeng Yu, Laychiluh Mekonnen, Journal of Medicinal Chemistry Chemoprevention StrategyPharmacotherapyCell CyclePharmaceutical ChemistryTumor Biology	2017	68
Targeting CDK9 for treatment of colorectal cancer Muhammed H. Rahaman, Frankie Lam, Long‐Jin Zhong, Molecular Oncology	2019	56
Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73 Frankie Lam, Abdullahi Y. Abbas, Hao Shao, Oncotarget	2014	53
Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells Theodosia Teo, Mingfeng Yu, Yuchao Yang, Cancer Letters Hematological MalignancyPharmacologic Co-inhibitionMixed-phenotype Acute LeukemiaTumor SuppressorRadiation Oncology	2014	43
Discovery of (<i>E</i>)-3-((Styrylsulfonyl)methyl)pyridine and (<i>E</i>)-2-((Styrylsulfonyl)methyl)pyridine Derivatives as Anticancer Agents: Synthesis, Structure–Activity Relationships, and Biological Activities Tiangong Lu, Aik Wye Goh, Mingfeng Yu, Journal of Medicinal Chemistry Anticancer AgentsStructure–activity RelationshipsChemical DerivativePharmaceutical ChemistryMedicinal Chemistry	2014	36
Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure–activity relationship analysis and biological evaluation Mingfeng Yu, Peng Li, Sunita K. C. Basnet, European Journal of Medicinal Chemistry Medicinal ChemistryPharmaceutical ChemistryBiochemistryNatural SciencesDrug Discovery	2015	34
Identification of a Novel Oligomerization Disrupting Mutation in<i>CRYΑA</i>Associated with Congenital Cataract in a South Australian Family Kate J. Laurie, Alpana Dave, Tania Straga, Human Mutation Congenital CataractOcular DiseaseOphthalmologyGeneticsSevere Visual Impairment	2012	33
Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia Theodosia Teo, Frankie Lam, Mingfeng Yu, Molecular Pharmacology	2015	29
An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis Theodosia Teo, Yuchao Yang, Mingfeng Yu, European Journal of Medicinal Chemistry Medicinal ChemistryIntegrated ApproachDrug TargetBiochemistryMedicine	2015	27

Page 1